Inflammatory biomarkers in polymyositis/dermatomyositis patients with interstitial lung disease: a retrospective study

被引:1
|
作者
Zhao, Jin [1 ,2 ,3 ]
Guo, Xiao-Jing [1 ,2 ,3 ]
Shi, Lei [4 ]
机构
[1] Shanxi Prov Canc Hosp, Dept Hematol, Taiyuan, Shanxi, Peoples R China
[2] Chinese Acad Med Sci, Canc Hosp, Shanxi Hosp, Dept Hematol, Taiyuan, Shanxi, Peoples R China
[3] Shanxi Med Univ, Canc Hosp, Dept Hematol, Taiyuan, Shanxi, Peoples R China
[4] Shanxi Med Univ, Hosp 2, Dept Rheumatol, Taiyuan, Shanxi, Peoples R China
关键词
Polymyositis; dermatomyositis; interstitial lung disease; risk factors; Treg cells; RHEUMATOID-ARTHRITIS; PULMONARY-FIBROSIS; POLYMYOSITIS; DERMATOMYOSITIS; LYMPHOCYTE; MORTALITY; MYOSITIS; RATIOS; RISK; TERM;
D O I
10.1080/03007995.2023.2281501
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundDermatomyositis (DM)/polymyositis (PM) is a systemic autoimmune disease characterized by proximal limb muscle with high morbidity and mortality and poor prognosis mediated by immune dysfunction; its etiology is unknown. DM/PM patients are at excessive risk of interstitial lung disease (ILD) and a higher risk of death. However, the role of circulating lymphocyte subsets, which play a pivotal role in occurrence and progression of DM/PM and ILD, respectively, remains unclear in DM/PM patients with ILD.MethodsDemographic characteristics, general data, and peripheral lymphocyte levels measured by flow cytometry were collected and analyzed in 47 DM/PM patients with ILD, 65 patients without ILD, and 105 healthy controls (HCs).ResultsThe most important first symptom of DM/PM patients is rash. Compared with non-ILD patients, the levels of neutrophil/lymphocyte ratio (NLR), systemic inflammatory response index (SIRI) were significantly higher and the levels of C reactive protein (CRP) were significantly lower in patients with ILD. Compared with HCs, DM/PM patients, with or without ILD, had decreased absolute counts of T, CD4 + T, CD8 + T, natural killer (NK), helper T (Th) 1, Th2, Th17, and regulatory T (Treg)cells. The fewest Th1 and Treg cells and the the lowest CD8 + T and Th1 cells percentages were seen in peripheral blood of patients with ILD. Longer duration, decreased lymphocyte/monocyte ratio (LMR)levels and CD8 + T and Th1 cells proportions, and fewer circulating Treg cells were independent risk factors for DM/PM with ILD.ConclusionsThe identification of peripheral blood T lymphocyte subsets, especially Treg cells, and blood count in DM/PM appears to be useful in the comprehensive assessment of clinical lung involvement.
引用
收藏
页码:113 / 122
页数:10
相关论文
共 50 条
  • [21] Pretreatment mortality risk prediction model in patients with polymyositis/dermatomyositis-associated interstitial lung disease
    Gui, Xianhua
    Li, Wangzhong
    Jiang, Hanyi
    Wang, Rujia
    Yu, Min
    Zhao, Tingting
    Ma, Miao
    Ding, Jingjing
    Jin, Ziyi
    Qiu, Yuying
    Qiu, Xiaohua
    Zhang, Yingwei
    Cao, Min
    Huang, Mei
    Cao, Mengshu
    Dai, Jinghong
    Cai, Hourong
    Xin, Xiaoyan
    Xiao, Yonglong
    RMD OPEN, 2024, 10 (02):
  • [22] Treatment of Interstitial Lung Disease Associated with Polymyositis-Dermatomyositis: An Update
    Takada, Toshinori
    Narita, Ichiei
    Suzuki, Eiichi
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2013, 9 (02) : 130 - 136
  • [23] Interstitial lung disease in polymyositis and dermatomyositis.
    Schnabel A.
    Hellmich B.
    Gross W.L.
    Current Rheumatology Reports, 2005, 7 (2) : 99 - 105
  • [24] Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease
    Li, Liubing
    Wang, Han
    Wang, Qian
    Wu, Chanyuan
    Liu, Chenxi
    Zhang, Yanfang
    Cheng, Linlin
    Zeng, Xiaofeng
    Zhang, Fengchun
    Li, Yongzhe
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 397 : 123 - 128
  • [25] Clinical Characteristics of Dermatomyositis with Interstitial Lung Disease: A Retrospective Case-Control Study
    Weng, Chenghua
    Ding, Zongnan
    Zhou, Yiqun
    Yang, Qinyi
    Xue, Leixi
    Zhang, Lei
    Wang, Gang
    Liu, Zhichun
    RHEUMATOLOGY AND THERAPY, 2023, 10 (03) : 635 - 648
  • [26] Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients With Dermatomyositis and Polymyositis
    Shimojima, Yasuhiro
    Ishii, Wataru
    Matsuda, Masayuki
    Kishida, Dai
    Ikeda, Shu-ichi
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2017, 23 (02) : 87 - 93
  • [27] Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis
    Ochi, S
    Nanki, T
    Takada, K
    Suzuki, R
    Komano, Y
    Kubota, T
    Miyasaka, N
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2005, 23 (05) : 707 - 710
  • [28] Interstitial lung disease in polymyositis and dermatomyositis
    Fathi, M
    Lundberg, IE
    CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (06) : 701 - 706
  • [29] Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease
    Hozumi, Hironao
    Fujisawa, Tomoyuki
    Enomoto, Noriyuki
    Nakashima, Ran
    Enomoto, Yasunori
    Suzuki, Yuzo
    Kono, Masato
    Karayama, Masato
    Furuhashi, Kazuki
    Murakami, Akihiro
    Inui, Naoki
    Nakamura, Yutaro
    Mimori, Tsuneyo
    Suda, Takafumi
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (09) : 1394 - 1401
  • [30] Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020
    Sun, Kun-Yan
    Fan, Yong
    Wang, Yun-Xia
    Zhong, Yi-Jue
    Wang, Guang-Fa
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2021, 51 (01) : 175 - 191